tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Rudy Li, 1 are a HOLD (3.57%), 27 are a BUY (96.43%).
Analyst Rudy Li, currently employed at WOLFE, carries an average stock price target met ratio of 59.72% that have a potential upside of 54.04% achieved within 145 days. Previously, Rudy Li worked at LEERINK.
Rudy Li’s has documented 55 price targets and ratings displayed on 6 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on CNTA, Centessa Pharmaceuticals PLC ADR at 31-Mar-2026.
Analyst best performing recommendations are on XENE (XENON PHARMACEUTICALS).
The best stock recommendation documented was for XENE (XENON PHARMACEUTICALS) at 2/24/2026. The price target of $60 was fulfilled within 13 days with a profit of $15.21 (33.96%) receiving and performance score of 26.12.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 21-Aug-2026
$40
$13.71 (52.15%)
$25
2 months 10 days ago
(21-Aug-2026)
4/6 (66.67%)
$7.71 (23.88%)
237
Buy Since 05-Jan-2026
$35
$8.71 (33.13%)
$35
2 months 27 days ago
(04-Aug-2026)
2/3 (66.67%)
$3.33 (10.51%)
12
Buy Since 08-Nov-2021
$40
$13.71 (52.15%)
$38
2 months 27 days ago
(04-Aug-2026)
6/10 (60%)
$8.33 (26.30%)
107
Buy Since 26-Apr-2023
$58
$31.71 (120.62%)
$60
2 months 27 days ago
(04-Aug-2026)
6/8 (75%)
$26.33 (83.14%)
453
Buy Since 12-Nov-2019
$39
$12.71 (48.35%)
$39
5 months 20 days ago
(11-May-2026)
4/7 (57.14%)
$6.36 (19.49%)
398
What Year was the first public recommendation made by Rudy Li?
